Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study
Davyson, E.; Shen, X.; Huider, F.; Adams, M.; Borges, K.; McCartney, D.; Barker, L.; Van Dongen, J.; Boomsma, D.; Weihs, A.; Grabe, H.; Kuehn, L.; Teumer, A.; Volzke, H.; Zhu, T.; Kaprio, J.; Ollikainen, M.; David, F. S.; Meinert, S.; Stein, F.; Forstner, A.; Dannlowski, U.; Kircher, T.; Tapuc, A.; Czamara, D.; Binder, E. B.; Bruckl, T.; Kwong, A.; Yousefi, P.; Wong, C. C.; Arseneault, L.; Fisher, H. L.; Mill, J.; Cox, S.; Redmond, P.; Russ, T. C.; Marioni, R. E.; Wray, N. R.; McIntosh, A. M.
Show abstract
ImportanceUnderstanding antidepressant mechanisms could help design more effective and tolerated treatments. ObjectiveIdentify DNA methylation (DNAm) changes associated with antidepressant exposure. DesignCase-control methylome-wide association studies (MWAS) of antidepressant exposure were performed from blood samples collected between 2006-2011 in Generation Scotland (GS). The summary statistics were tested for enrichment in specific tissues, gene ontologies and an independent MWAS in the Netherlands Study of Depression and Anxiety (NESDA). A methylation profile score (MPS) was derived and tested for its association with antidepressant exposure in eight independent cohorts, alongside prospective data from GS. SettingCohorts; GS, NESDA, FTC, SHIP-Trend, FOR2107, LBC1936, MARS-UniDep, ALSPAC, E-Risk, and NTR. ParticipantsParticipants with DNAm data and self-report/prescription derived antidepressant exposure. Main Outcome(s) and Measure(s)Whole-blood DNAm levels were assayed by the EPIC/450K Illumina array (9 studies, Nexposed = 661, Nunexposed= 9,575) alongside MBD-Seq in NESDA (Nexposed= 398, Nunexposed= 414). Antidepressant exposure was measured by self- report and/or antidepressant prescriptions. ResultsThe self-report MWAS (N = 16,536, Nexposed = 1,508, mean age = 48, 59% female) and the prescription-derived MWAS (N = 7,951, Nexposed = 861, mean age = 47, 59% female), found hypermethylation at seven and four DNAm sites (p < 9.42x10-8), respectively. The top locus was cg26277237 (KANK1, pself-report= 9.3x10-13, pprescription = 6.1x10-3). The self-report MWAS found a differentially methylated region, mapping to DGUOK-AS1 (padj = 5.0x10-3) alongside significant enrichment for genes expressed in the amygdala, the "synaptic vesicle membrane" gene ontology and the top 1% of CpGs from the NESDA MWAS (OR = 1.39, p < 0.042). The MPS was associated with antidepressant exposure in meta-analysed data from external cohorts (Nstudies= 9, N = 10,236, Nexposed = 661, f3 = 0.196, p < 1x10-4). Conclusions and RelevanceAntidepressant exposure is associated with changes in DNAm across different cohorts. Further investigation into these changes could inform on new targets for antidepressant treatments. 3 Key PointsO_ST_ABSQuestionC_ST_ABSIs antidepressant exposure associated with differential whole blood DNA methylation? FindingsIn this methylome-wide association study of 16,536 adults across Scotland, antidepressant exposure was significantly associated with hypermethylation at CpGs mapping to KANK1 and DGUOK-AS1. A methylation profile score trained on this sample was significantly associated with antidepressant exposure (pooled f3 [95%CI]=0.196 [0.105, 0.288], p < 1x10-4) in a meta-analysis of external datasets. MeaningAntidepressant exposure is associated with hypermethylation at KANK1 and DGUOK-AS1, which have roles in mitochondrial metabolism and neurite outgrowth. If replicated in future studies, targeting these genes could inform the design of more effective and better tolerated treatments for depression.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Epigenome-wide association study of self-reported antidepressant use in Generation Scotland implicates the innate immune system 95%
- Immunological Drivers and Potential Novel Drug Targets for Major Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions 95%
- Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium 95%
Similar papers in this journal
- Differential and spatial expression meta-analysis of genes identified in genome-wide association studies of depression 95%
- Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation 95%
- Transcriptional-Regulatory Convergence Across Functional MDD Risk Variants Identified by Massively Parallel Reporter Assays 94%
Similar papers in this journal
- Evidence for a serotonergic subtype of major depressive disorder: A NeuroPharm-1 study. 94%
- Decoding Treatment Choice: Genetic and Phenotypic Analyses of Long-term Antidepressant Acceptability 93%
- A Survey of Copy Number Variants Associated with Neurodevelopmental Disorders in a Large-Scale, Multi-Ancestry Biobank 92%
Similar papers in this journal
Similar papers in this journal
- A methylome-wide association study of major depression with out-of-sample case-control classification and trans-ancestry comparison 95%
- Evaluating the causal relationship between educational attainment and mental health 93%
- Dissecting causal relationships between cortical morphology and neuropsychiatric disorders: a bidirectional Mendelian randomization study 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.